PLX•prnewswire•
Protalix BioTherapeutics Letter to Stockholders
Summary
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 5, 2026 by prnewswire